Many doctors and health plans, however, hold safety and cost control concerns about a labeling change. Celebrex and Vioxx cost roughly 20 times more than ibuprofren, and insurers believe that a ...

Back in 2004, a popular arthritis drug called Vioxx was pulled off the market when studies showed daily long-term use could increase the risk of heart attack, stroke and death. “This was one of the ...

A federal lawsuit filed in Roanoke against the makers of the pain medication Celebrex claims the drug either caused or contributed to a Tazewell County woman's death in 2003. The lawsuit joins a ...

GAITHERSBURG, Md. — Pfizer Inc. should get American approval to market its Celebrex arthritis-pain pill for use in children because the benefits outweigh the risks, a Food and Drug Administration ...

The maker of the best-selling arthritis drug Celebrex will not be allowed to claim that its product is safer for the stomach and digestive tract than older, less expensive arthritis medicines, the ...

Jeffrey Brown talks with health correspondent Susan Dentzer and Dr. John Reveille, director of the Division of Rheumatology at the University of Texas Health Science Center in Houston, about the ...

The addition of aspirin appears to the modify the cardiovascular and overall safety of nonsteroidal anti-inflammatory drug (NSAID) therapy, specifically the beneficial safety profile of celecoxib over ...

Jiayuh Lin, PhD, and colleagues at Nationwide Children's Hospital have developed a drug to target the most common cancerous bone tumor in children, osteosarcoma, using a version of the FDA-approved ...

The findings, stemming from basic science research and a retrospective analysis, are particularly concerning given changes to the drug’s label clearing low-dose celecoxib against charges of an ...

When Merck pulled its prescription pain reliever Vioxx from the market at the end of September, citing safety concerns, Pfizer moved swiftly to tout its rival drug Celebrex with a new campaign. Ads ...

LONDON, UK — Both CV-event rates and prevalence of serious gastrointestinal complications were surprisingly low in people without heart disease taking either celecoxib (Celebrex, Pfizer) or ...